Back

90K/LGALS3BP Expression is Upregulated in COVID-19 but Does Not Restrict SARS-CoV-2 Infection

Bosquillon de Jarcy, L.; Akbil, B.; Leyens, J.; Postmus, D.; Harnisch, G.; Jansen, J.; Schmidt, M.; Aigner, A.; Pott, F.; Chua, R. L.; Krist, L.; Gentile, R.; Muehlemann, B.; Jones, T. C.; Niemeyer, D.; Fricke, J.; Keil, T.; Pischon, T.; Janke, J.; Conrad, C.; Iacobelli, S.; Drosten, C.; Corman, V. M.; Ralser, M.; Eils, R.; Kurth, F.; Sander, L. E.; Goffinet, C.

2022-07-19 respiratory medicine
10.1101/2022.07.18.22277255 medRxiv
Show abstract

Glycoprotein 90K, encoded by the interferon-stimulated gene LGALS3BP, displays broad antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate immune signaling. Here, we analyzed the expression of 90K/LGALS3BP in 44 hospitalized COVID-19 patients. 90K protein serum levels were significantly elevated in COVID-19 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC scRNA-seq datasets uncovered monocyte-specific induction of LGALS3BP mRNA expression in COVID-19 patients. In functional assays, neither 90K overexpression in susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-CoV-2 infection. Our data suggests that 90K/LGALS3BP contributes to the global type I IFN response during SARS-CoV-2 infection in vivo without displaying detectable antiviral properties.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.